Real‐world experience in treating pediatric relapsed/refractory or therapy‐related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium-Reference-Cited by-同舟云学术

Real‐world experience in treating pediatric relapsed/refractory or therapy‐related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium

Published:2022-06-21 Issue:10 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Schafer Eric S.¹²^ORCID,Chao Karen³^ORCID,Stevens Alexandra M.¹²,Jo Eunji¹,Hilsenbeck Susan G.¹,Gossai Nathan P.⁴,Doan Andrew⁵^ORCID,Colace Susan I.⁶,Guinipero Terri⁶,Otterson Daniel³,Kaplan Joel A.⁷,Hinson Ashley⁷^ORCID,Pommert Lauren⁸⁹^ORCID,Wayne Alan S.⁵,Bhojwani Deepa⁵,Burke Michael J.³^ORCID

Affiliation:

1. Baylor College of Medicine Houston Texas USA

2. Texas Children's Cancer Center Houston Texas USA

3. Medical College of Wisconsin Milwaukee Wisconsin USA

4. Center for Cancer and Blood Diseases Children's Minnesota Minneapolis Minnesota USA

5. Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine University of Southern California Los Angeles California USA

6. Nationwide Children's Hospital Columbus Ohio USA

7. Levine Children's Hospital/Carolinas Medical Center Charlotte North Carolina USA

8. Division of Oncology Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

9. Department of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USA

Funder

Curing Kids Cancer

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29812